Please login to the form below

Not currently logged in
Email:
Password:

Nycomed/Almirall sign China deal

Swiss firm Nycomed has signed an agreement to market Spain-based pharmaceutical company Almirall’s antihistamine Kestine (ebastine) in China and other markets in Southeast Asia

Swiss firm Nycomed has signed an agreement to market Spain-based pharmaceutical company Almirall's antihistamine Kestine (ebastine) in China and other markets in Southeast Asia.

As part of the deal, Nycomed will hold exclusive commercialisation rights for Kestine in China, where the product is already available, as well as rights for the drug once it is launched in Malaysia, Philippines, Singapore, Thailand and Indonesia.

Kestine, prescribed for the treatment of allergic rhinitis and chronic idiopathic urticaria, is already approved for marketing in 30 countries.
Financial details of the agreement were not disclosed.

Guido Oelkers, executive vice president, Commercial Operations at Nycomed explained the deal would support the company's development in Asia.

He said: "Emerging markets continue to be our focus area for future growth."

29th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics